https://idataresearch.com/wp-content/themes/lambda-child-theme/images/idata-white-logo.png

Hyaluronic Acid Visco-supplementation

Showing all 9 results

Orthobiologics Market Analysis, Size, Trends | China | 2020-2026 | MedSuite

In 2020, the Chinese orthobiologics market size was valued at $460.7 million, with over 424,000 bone grafting procedures performed every year. The market size is expected to increase at a compound annual growth rate (CAGR) of 6% to reach $690.8 million in 2026. Throughout this medical market research, we analyzed 28 orthobiologics companies across China

more...

Orthobiologics Market Analysis, Size, Trends | India | 2020-2026 | MedSuite

In 2020, the Indian orthobiologics market size was valued at $76.2 million, with over 520,000 bone grafting procedures performed every year. The market size is expected to increase at a compound annual growth rate (CAGR) of 12.4% to reach $172.3 million in 2026. Throughout this medical market research, we analyzed 23 orthobiologics companies across India

more...

Orthobiologics Market Analysis, Size, Trends | Japan | 2020-2026 | MedSuite

In 2020, the Japanese orthobiologics market size was valued at $426.9 million, with over 221,000 bone grafting procedures performed every year. The market size is expected to fluctuate over the forecast period with a -0.4% compound annual growth rate (CAGR). Throughout this medical market research, we analyzed 16 orthobiologics companies across Japan and used our

more...

Orthobiologics Market Analysis, Size, Trends | South Korea | 2020-2026 | MedSuite

In 2020, the South Korean orthobiologics market size was valued at $141.6 million, with over 200,000 bone grafting procedures performed every year. The market size is expected to increase at a compound annual growth rate (CAGR) of 3.6% to reach $181.5 million in 2026. Throughout this medical market research, we analyzed 16 orthobiologics companies across

more...

Orthobiologics Market Analysis, Size, Trends | Australia | 2020-2026 | Medsuite

In 2020, the Australian orthobiologics market size was valued at $63.8 million, with over 29,000 bone grafting procedures performed every year. The market size is expected to increase at a compound annual growth rate (CAGR) of 4.9% to reach $89.4 million in 2026. Throughout this medical market research, we analyzed 48 orthobiologics companies across Australia

more...

Orthopedic Biomaterials Market Size, Share and COVID-19 Impact Analysis | Global | 2023-2029 | MedSuite | Includes: Bone Graft Substitutes, Orthopedic Growth Factors, and 3 more

Overall, the global orthopedic biomaterials device market was valued at $5.6 billion in 2022. This is expected to increase over the forecast period at a CAGR of 3.4% to reach $7.1 billion.

more...

Orthopedic Biomaterials Market Size, Share and COVID-19 Impact Analysis | Europe | 2022-2028 | MedSuite | Includes: Bone Graft Substitutes, Orthopedic Growth Factors, and 3 more

The European Orthopedic Biomaterials market report covers and includes the Bone Graft Substitutes Market, Orthopedic Growth Factor Market , Orthopedic Cell Therapy Market, Hyaluronic Acid Viscosupplementation Market, and the Orthopedic Cartilage Repair Market.

more...

Orthopedic Biomaterials Market Size, Share & COVID-19 Impact Analysis | United States | 2022-2028 | MedSuite | Includes: Orthopedic Bone Graft Substitutes (Allografts, Demineralized Bone Matrices (DBMs), Xenografts, and Synthetic Bone Graft) , Orthopedic Growth Factor, and 4 more

Overall, the U.S. Orthopedic Biomaterials market was valued at $3.7 billion in 2021. This is expected to increase over the forecast period at a CAGR of 3.6% to reach $4.7 billion. Demographic factors in the U.S. continue to be the largest driver within the orthopedic biomaterials market. This is primarily due to the growing elderly

more...

Orthopedic Hyaluronic Acid Market Analysis | Canada | 2016-2022 | MedCore

One of the market limiters for the Canadian HA market is the reimbursement structure. None of the products are covered under standard healthcare plans and must be purchased directly or through extended healthcare coverage or private insurance. Thus, some patients opt out to receiving cortisone injections; these are reimbursed by standard healthcare and are a more affordable choice.
One of the factors that contributed positively to this market is ever expanding indication. The market originally started with treating osteoarthritis (OA) of the knee, since then some products expanded into hip, shoulder, a number of small joints, as well as assisting with post-surgery joint recovery.

more...